Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
出版年份 2018 全文链接
标题
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
作者
关键词
-
出版物
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 215, Issue 2, Pages 681-697
出版商
Rockefeller University Press
发表日期
2018-01-04
DOI
10.1084/jem.20171288
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Letter
- (2016) A. Zucchetto et al. CLINICAL CANCER RESEARCH
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia
- (2016) Elisa ten Hacken et al. JOURNAL OF IMMUNOLOGY
- CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia
- (2016) M Dal Bo et al. LEUKEMIA
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
- (2015) M. F. M. de Rooij et al. BLOOD
- Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
- (2015) T.-M. Liu et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
- (2015) Philip A. Thompson et al. CANCER
- Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
- (2015) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
- (2015) M. F. M. de Rooij et al. HAEMATOLOGICA
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
- (2015) A. Wiestner HAEMATOLOGICA
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
- (2015) S-S Chen et al. LEUKEMIA
- CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21
- (2015) Sylvia Ganghammer et al. Oncotarget
- Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
- (2015) M. F. M. de Rooij et al. HAEMATOLOGICA
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
- (2015) A. Wiestner HAEMATOLOGICA
- How will B-cell-receptor-targeted therapies change future CLL therapy?
- (2014) J. A. Jones et al. BLOOD
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
- (2014) J. A. Woyach et al. BLOOD
- Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia
- (2014) Philip A. Thompson et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD49d Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia
- (2014) Pietro Bulian et al. JOURNAL OF CLINICAL ONCOLOGY
- Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician
- (2014) John C. Byrd et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
- (2014) S E M Herman et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
- (2014) A. Wiestner Hematology-American Society of Hematology Education Program
- Targeting B-cell anergy in chronic lymphocytic leukemia
- (2013) B. Apollonio et al. BLOOD
- CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism
- (2013) A. Zucchetto et al. BLOOD
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
- (2012) H. Thorvaldsdottir et al. BRIEFINGS IN BIOINFORMATICS
- The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells
- (2012) A Zucchetto et al. LEUKEMIA
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Unknown
- (2011) Carlo Calissano et al. MOLECULAR MEDICINE
- A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer.
- (2010) A Storniolo et al. CANCER RESEARCH
- Real-time Analysis of Conformation-sensitive Antibody Binding Provides New Insights into Integrin Conformational Regulation
- (2009) Alexandre Chigaev et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential
- (2008) Tait D. Shanafelt et al. BRITISH JOURNAL OF HAEMATOLOGY
- Activation of the Small GTPase Rac2 via the B Cell Receptor Regulates B Cell Adhesion and Immunological-Synapse Formation
- (2008) Eloisa Arana et al. IMMUNITY
- Regulation of integrin activation through the B-cell receptor
- (2008) E. Arana et al. JOURNAL OF CELL SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now